Navigation Links
VetStem Biopharma Begins Enrollment in Pivotal FDA Clinical Study of Osteoarthritis in Dogs
Date:11/17/2016

VetStem Biopharma, Inc. announced initiation of a pivotal field effectiveness and safety study to evaluate the clinical efficacy and safety of its investigational allogeneic adipose stem cell product. The randomized and blinded placebo-controlled, multi-center study in dogs with clinical osteoarthritis is expected to be completed and submitted to U.S. Food and Drug Administration (FDA) in 2017. The study is being conducted under an FDA-concurred protocol and is supported by VetStem’s US commercial licensee, Aratana Therapeutics.

This pivotal field efficacy study will enroll more than 200 dogs at 17 US veterinary clinics. The stem cell product or placebo will be given as a single injection.

This stem cell product was tested in a large, blinded dose confirmation study and the results were published in the peer-reviewed publication, Frontiers in Veterinary Science and titled “A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs.” Study results showed dogs that received the intraarticular injection of stem cells demonstrated a statistically significant improvement in treatment versus placebo (p<0.05).

Bob Harman, DVM, MPVM, CEO of VetStem stated, “Stem cell therapy for osteoarthritis is a truly novel approach to treatment of a devastating clinical condition of dogs. Donor-derived allogeneic stem cells provide cell therapy in a “ready to use” format without the need for tissue collection, processing or cell culture. VetStem looks forward to the results from this pivotal study, and if favorable, to submitting a major part of the effectiveness data package to the FDA.” If approved, the Company will begin commercialization.

The Company’s stated mission is “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” This pivotal study is a key milestone on the path to bring the Company’s first product to market. If approved, this product will be marketed in the US by Aratana Therapeutics, VetStem’s US licensee and commercial partner. VetStem is also in the process of seeking EMA authorization for launch of this product in the European markets and seeks EU and other ex-USA territory commercialization partners.

About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The Company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at http://www.prweb.com/releases/2016/11/prweb13839025.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. Beckman Coulter Webinar Helps You Skirt the Pitfalls When Automating Cell Viability Counting for Biopharma QC
2. U.S. Ranks 1st in How Its National Policies Impact Global Biopharma Innovation, ITIF Finds in New Analysis Marking World Health Day
3. Reliable Biopharmaceutical Announces New Investor and Chairman
4. Optimizing Early Stage Drug Development and Best Practices in Clinical Trial Supply Management to be Presented by Catalent Experts at Biopharma Asia in Singapore
5. FDAnews Announces — The Biopharmaceutical Facility of the Future: To 2025 and Beyond Webinar, Sept. 29, 2015
6. Dr. Kevin Sadati Discusses the Impact of Allergan Acquiring KYTHERA Biopharmaceuticals
7. Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc.
8. Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting
9. ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug
10. Membrane Technology Market in Pharmaceutical, Biopharma and Life Sciences by Transparency Market Research
11. Keryx Biopharmaceuticals receives FDA approval of ferric citrate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Ecocor , ... Richard Pedranti Architect (RPA), a full-service architecture firm focusing on sustainable design, ... Line of Model Homes . Independently, Ecocor and RPA have extensive experience with ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... inaugural SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student ... MS in Educational Leadership and Administration at St. Thomas University in Miami, Florida, ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with a Curse: ... tithe, and the freedom experienced when breaking free from this misconception. “Cursed with ... M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s new book ...
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... “Letters From Home”: a moving compilation of letters that ... God. “Letters From Home” is the creation of published author, John Allred, a passionate ... Jerry Savelle Ministries International, who has traveled and ministered on four continents. , “It ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
Breaking Medicine Technology: